RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 133 filers reported holding RECURSION PHARMACEUTICALS IN in Q2 2022. The put-call ratio across all filers is 0.76 and the average weighting 2.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,880,104 | +299.2% | 899,360 | +289.8% | 0.00% | – |
| Q2 2023 | $1,723,464 | -53.6% | 230,718 | -58.6% | 0.00% | – |
| Q1 2023 | $3,715,257 | +14.2% | 557,010 | +32.0% | 0.00% | – |
| Q4 2022 | $3,252,571 | +53.7% | 421,864 | +112.1% | 0.00% | – |
| Q3 2022 | $2,116,000 | +144.9% | 198,866 | +87.2% | 0.00% | – |
| Q2 2022 | $864,000 | +44.2% | 106,217 | +26.9% | 0.00% | – |
| Q1 2022 | $599,000 | -79.6% | 83,680 | -51.1% | 0.00% | – |
| Q4 2021 | $2,932,000 | +380.7% | 171,175 | +545.8% | 0.00% | – |
| Q3 2021 | $610,000 | +111.8% | 26,507 | +236.5% | 0.00% | – |
| Q2 2021 | $288,000 | – | 7,877 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Data Collective IV GP, LLC | 5,941,120 | $45,806,035 | 48.11% |
| Kinnevik AB (publ) | 7,653,061 | $59,005,100 | 33.28% |
| MV Management XI, L.L.C. | 1,971,908 | $15,203,411 | 26.45% |
| MIC Capital Management UK LLP | 8,451,758 | $65,163,057 | 12.86% |
| ArchPoint Investors | 1,114,626 | $8,593,766 | 4.07% |
| HARVARD MANAGEMENT CO INC | 1,509,254 | $11,636,348 | 1.44% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,710,339 | $20,896,714 | 0.80% |
| Duquesne Family Office | 1,385,950 | $10,685,675 | 0.53% |
| ALLEN OPERATIONS LLC | 217,657 | $1,678,135 | 0.45% |
| Artal Group S.A. | 960,204 | $7,403 | 0.41% |